Researchers from Harvard University’s Dana-Farber Cancer Institute are in pursuit of pancreatic cancer therapies through a surprising source: a chemical found in cannabis. According to the recent study, FBL-03G demonstrates significantly therapy potential in treatment of pancreatic cancer. Enter Flavocure Biotech.
Pancreatic cancer is deadly. Making up 3% of all cancers in America it has a one-year survival rate of just 20% (5 -year survival rate of less than 8). The Pancreatic Cancer Action Network predicts it will be America’s second leading cause of cancer-related death by 2020. There is no cure.
Harvard/Flavocure Biotech Research
In a recent study published the Journal Frontiers of Oncology, the team found that the flavonoid derivative of cannabis demonstrates significant therapy potential in the treatment of pancreatic cancer, including radio-sensitizing and cancer metastasis treatment potential. The results justify further studies, the researchers declared, to optimize therapy outcomes toward clinical translation.
Harvard’s Dana-Farber has been a key catalyst as they decided to take the therapeutic potential of FBL-03G and test it against pancreatic cancer via a lab experiment. The key researcher there is Wilfred Ngwa, PhD.
What is FBL-03G?
Produced by Flavocure Biotech, FBL-03G represents an exciting collaboration with Harvard Medical School. The results of the FBL-03G molecule have shown statistically significant results against Pancreatic cancer in vivo. The company plans to continue their collaboration with Harvard to advance FBL-03G towards an improved treatment and a cure for pancreatic cancer.
FBL-03G has exhibited promise against glioblastoma, a deadly form of brain cancer and other solid tumors. Flavocure seeks additional funding to pursue glioblastoma. The company expects that FBL-035 will be their second FDA designated Orphan Drug. Under the Orphan Drug Act, the designation/approval by the FDA would grant Flavocure benefit of FDA/EMA sanctioned exclusivity on the drug for 7 years in the U.S. and 10 years in Europe in addition to any patent protections.
The drug is derived from cannabis flavonoids which make up just 0.14% of the plant. A challenge as researchers would need many fields of plants. However, this challenge was recently overcome as scientists have found a way to genetically engineer cannabis flavonoids—now making it feasible to investigate their benefits.
Based in Baltimore, they were formed in 2018 to discover and develop cannabis derived molecules. They formed a partnership with Harvard and attracted $1.5 million from one of Asia’s richest tycoons via the Denning Growth Fund (DGF).
IND Readiness Studies
Flavocure announced investment in IND readiness studies (e.g. preclinical) at the beginning of 2019. The initial study cost is expected to be over $1 million and has been independently sponsored by the Flavocure’s Executive Vice Chairman, Clark Swanson. These independent financial commitments, critically important, are paving the way for Flavocure to attain IND status from the FDA (which of course would allow them to proceed with clinical trials). The effort was expected to be completed by end of 2019. Flavocure hired a reputable clinical research organization (CRO) to conduct the preclinical studies.
The Potential Market
Flavocure estimates that the FBL-03G molecule targets a patient market growing at 8.1% CAGR and represents over $2.5 billion annually based on the therapeutic target and implicated cancers.
Wilfred Ngwa, MS, PhD, Assistant Professor, Radiation Oncology, Harvard Medical School